BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 10491431)

  • 1. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
    Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
    J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
    Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J
    FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
    Lal B; Xia S; Abounader R; Laterra J
    Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.
    Bowers DC; Fan S; Walter KA; Abounader R; Williams JA; Rosen EM; Laterra J
    Cancer Res; 2000 Aug; 60(15):4277-83. PubMed ID: 10945642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity.
    Liang H; O'Reilly S; Liu Y; Abounader R; Laterra J; Maher VM; McCormick JJ
    Int J Oncol; 2004 May; 24(5):1057-67. PubMed ID: 15067326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma.
    Abounader R; Ranganathan S; Kim BY; Nichols C; Laterra J
    J Neurochem; 2001 Mar; 76(5):1497-508. PubMed ID: 11238734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.
    Davies G; Watkins G; Mason MD; Jiang WG
    Prostate; 2004 Sep; 60(4):317-24. PubMed ID: 15264243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET.
    Jiang WG; Grimshaw D; Martin TA; Davies G; Parr C; Watkins G; Lane J; Abounader R; Laterra J; Mansel RE
    Clin Cancer Res; 2003 Sep; 9(11):4274-81. PubMed ID: 14519655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
    Moriyama T; Kataoka H; Koono M; Wakisaka S
    Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP.
    Hamasuna R; Kataoka H; Moriyama T; Itoh H; Seiki M; Koono M
    Int J Cancer; 1999 Jul; 82(2):274-81. PubMed ID: 10389763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.
    Cao B; Su Y; Oskarsson M; Zhao P; Kort EJ; Fisher RJ; Wang LM; Vande Woude GF
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7443-8. PubMed ID: 11416216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas.
    Kunkel P; Müller S; Schirmacher P; Stavrou D; Fillbrandt R; Westphal M; Lamszus K
    Neuro Oncol; 2001 Apr; 3(2):82-8. PubMed ID: 11296484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
    Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
    Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells.
    Jiang WG; Grimshaw D; Lane J; Martin TA; Abounader R; Laterra J; Mansel RE
    Clin Cancer Res; 2001 Aug; 7(8):2555-62. PubMed ID: 11489839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo.
    Uchinokura S; Miyata S; Fukushima T; Itoh H; Nakano S; Wakisaka S; Kataoka H
    Int J Cancer; 2006 Feb; 118(3):583-92. PubMed ID: 16106403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
    Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth.
    Laterra J; Rosen E; Nam M; Ranganathan S; Fielding K; Johnston P
    Biochem Biophys Res Commun; 1997 Jun; 235(3):743-7. PubMed ID: 9207232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.
    Gao CF; Xie Q; Zhang YW; Su Y; Zhao P; Cao B; Furge K; Sun J; Rex K; Osgood T; Coxon A; Burgess TL; Vande Woude GF
    Mol Cancer Ther; 2009 Oct; 8(10):2803-10. PubMed ID: 19825800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
    Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
    J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.